Now showing items 1-2 of 2

    • Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. 

      Bridgeman, VL; Vermeulen, PB; Foo, S; Bilecz, A; Daley, F; Kostaras, E; Nathan, MR; Wan, E; Frentzas, S; Schweiger, T; Hegedus, B; Hoetzenecker, K; Renyi-Vamos, F; Kuczynski, EA; Vasudev, NS; Larkin, J; Gore, M; Dvorak, HF; Paku, S; Kerbel, RS; Dome, B; Reynolds, AR (2017-02)
      Anti-angiogenic therapies have shown limited efficacy in the clinical management of metastatic disease, including lung metastases. Moreover, the mechanisms via which tumours resist anti-angiogenic therapies are poorly ...
    • Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. 

      Frentzas, S; Simoneau, E; Bridgeman, VL; Vermeulen, PB; Foo, S; Kostaras, E; Nathan, M; Wotherspoon, A; Gao, Z-H; Shi, Y; Van den Eynden, G; Daley, F; Peckitt, C; Tan, X; Salman, A; Lazaris, A; Gazinska, P; Berg, TJ; Eltahir, Z; Ritsma, L; Van Rheenen, J; Khashper, A; Brown, G; Nystrom, H; Sund, M; Van Laere, S; Loyer, E; Dirix, L; Cunningham, D; Metrakos, P; Reynolds, AR (2016-11)
      The efficacy of angiogenesis inhibitors in cancer is limited by resistance mechanisms that are poorly understood. Notably, instead of through the induction of angiogenesis, tumor vascularization can occur through the ...